| Code | CSB-RA004936MB14HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to LNF-1901, targeting CD40, a critical costimulatory receptor belonging to the tumor necrosis factor receptor superfamily. CD40 is primarily expressed on antigen-presenting cells, including B cells, dendritic cells, and macrophages, where it plays a pivotal role in adaptive immunity by regulating B cell activation, immunoglobulin class switching, and T cell priming. The CD40-CD40L signaling pathway is implicated in various autoimmune disorders, inflammatory conditions, and hematological malignancies, making it an important therapeutic target for immune modulation research.
LNF-1901 represents an investigational antibody designed to modulate CD40 signaling pathways with potential applications in cancer immunotherapy and autoimmune disease research. This biosimilar provides researchers with a valuable tool for investigating CD40-mediated immune responses, exploring novel immunotherapeutic strategies, and studying the molecular mechanisms underlying immune cell activation and differentiation. The antibody supports diverse experimental approaches in immunology, oncology, and translational medicine research.
There are currently no reviews for this product.